Abstract:
A method for inhibiting the activity of 3-hydroxy-3-methylglutaryl CoA(HMG--CoA) reductase in mammals is disclosed comprising administering naringin or naringenin thereto.
Abstract:
Methods for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal comprise administering naringin or naringenin thereto.
Abstract:
A method for treating or preventing an elevated blood lipid level-related diseases such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and hepatic diseases in a mammal, which comprises administering thereto an effective amount of tannin, gallic acid or ellagic acid.
Abstract:
A method for lowering the blood glucose level in a mammal comprises administering an effective amount of a hesperetin or naringenin bioflavonoid.
Abstract:
0A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.
Abstract:
A method for treating or preventing an elevated blood lipid level-related disease such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and hepatic diseases in a mammal, which comprises administering thereto an effective amount of a cinnamic acid derivative of formula Ia or Ib, or a pharmaceutically acceptable salt thereof: wherein, R1, R2, R3, R4 and R5 are independently H, OH or C1-4 alkoxy; and R6 is H, C1-4 alkyl group, or C5-7 cycloalkyl group having one or more substituents selected from the group consisting of OH, alkoxy and carboxy groups.
Abstract:
A method for increasing the plasma high density lipoprotein(HDL) level in a mammal comprises administering a bioflavonoid of formula(I) or plant extract containing same thereto: ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5.sub.7 R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently hydrogen; a hydroxy group; a C.sub.1-9 alkoxy group optionally substituted with one or more substituents selected from the group consisting of a hydroxy, C.sub.1-5 alkoxy, aryloxy, and phenyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen, nitro and amido group; a C.sub.5-9 cycloalkyloxy group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen, nitro and amido group; a C.sub.5-9 cycloalkylcarbonyloxy group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen, nitro and amido group; a C.sub.2-10 or C.sub.16-18 acyloxy group optionally substituted with one or more substituents selected from the group consisting of a hydroxy, C.sub.1-5 alkoxy, aryloxy, and phenyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen and nitro group; a rutinosyl group; or a rhaminosyl group; andX is a single or double bond.
Abstract:
A method for inhibiting the activity of 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase in mammals comprises administering hesperidin or hesperetin thereto.
Abstract:
A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.
Abstract:
The present invention relates to a spice composition comprising 1 to 30 % by weight of garlic, 10 to 50% by weight of onion, 0.2 to 10% by weight of ginger, 5 to 40% by weight of jujube, and 10 to 50% by weight of citrus peel or an extract thereof or 1 to 20% by weight of naringin or hesperidin.